Bayer is close to EU approval for the drug Acoramidis, developed for the treatment of the rare and deadly heart disease transthyretin amyloidosis with cardiomyopathy. The Committee for Medicinal Products for Human Use of the European Medicines Agency (EMA) has recommended approval of the drug, as the DAX company announced on Thursday. A final decision by the EMA is expected at the beginning of 2025, with the agency usually following the committee's vote.
Bayer plans to launch the drug in Europe in the first half of 2025.
Acoramidis aims to stabilize the protein transthyretin (TTR), which becomes unstable in affected patients and deposits in the heart in the form of amyloid. These deposits lead to progressive heart failure that is fatal without treatment. According to studies, Acoramidis stabilizes the protein by at least 90 percent.
Transthyretin amyloidosis with cardiomyopathy mostly occurs in older adults and is considered a rare but serious disease. The use of Acoramidis could represent a much-needed treatment option for many patients.
Despite the positive developments, the stock market reacted cautiously: Bayer's stock was temporarily down 1.22 percent at 19.93 euros on Thursday via XETRA.
